A daily pill lowers lipoprotein(a) by a third — modestly, but cheaply

Obicetrapib, a once-daily oral cholesterol drug, lowered lipoprotein(a) by 37.3% and LDL cholesterol by 37.0% against placebo in a pooled analysis of high-risk patients [s1]. That makes it the rare pill that touches Lp(a) — a largely genetic, hard-to-shift lipid that a wave of expensive injectable RNA drugs is built to attack — though it moves the marker far less than those agents and has not yet been shown to prevent a single heart attack [s1].

Lp(a) is an LDL-like particle whose level is set mostly by inheritance and barely budges with statins, diet or exercise. High levels raise the risk of heart attack, stroke and aortic stenosis, which is why drugmakers have raced to lower it. Obicetrapib was not designed for that job: it blocks cholesteryl ester transfer protein (CETP), a target pursued chiefly to cut LDL. Lowering Lp(a) is a side effect that this analysis set out to quantify [s1].

What the pooled analysis found

The study combined trials testing 12 weeks of obicetrapib 10 mg daily against placebo in 2,356 patients with either inherited high cholesterol or established cardiovascular disease [s1]. The group was high-risk and heavily pre-treated: median age 66, 82% with atherosclerotic disease, 27% with heterozygous familial hypercholesterolaemia, and 91% already on a statin [s1]. Median baseline LDL cholesterol was 92 mg/dL, apolipoprotein B 87 mg/dL, and Lp(a) 42.9 nmol/L [s1]. That most were already at guideline-range LDL on a statin matters: the reductions below are what obicetrapib added on top of existing therapy, not what it can do alone [s1].

Placebo-adjusted, obicetrapib cut LDL cholesterol by 37.0% (35 mg/dL), apolipoprotein B by 21.3% (20 mg/dL), and Lp(a) by 37.3% (14.9 nmol/L) [s1]. The Lp(a) effect was larger in relative terms among patients whose starting level was moderately raised — a 43.3% reduction, or 36.3 nmol/L, in those between 50 and 150 nmol/L [s1]. Patients with the highest baseline levels, above 150 nmol/L, saw a smaller percentage fall but a similar absolute drop, 32.3 versus 36.3 nmol/L [s1].

That last detail is the analysis's real argument. The authors note that people with only mildly elevated Lp(a) are unlikely to qualify for the RNA-targeted drugs now in late trials, which are being tested in patients with very high levels — so a pill delivering a meaningful absolute reduction across the milder range could fill a gap those injectables leave open [s1].

Safety over a year

A separate pooled safety analysis of two phase 3 trials followed 2,880 patients on obicetrapib or placebo for 365 days [s2]. Overall adverse-event rates were similar, 60.2% versus 62.0%, and events leading to discontinuation were slightly fewer on the drug, 4.1% versus 5.3% [s2]. There was no clinically significant blood-pressure change between groups and no difference in liver or muscle measures [s2]. A decline in kidney filtration occurred less often on obicetrapib, 6.7% versus 8.7% [s2]. Macular degeneration was reported once, in a single patient [s2]. That safety cohort of 2,880 was similar in makeup to the lipid analysis — mean age 64, 36% women, 82% with cardiovascular disease — but 35.8% also had diabetes, a group in whom the glucose effects of lipid drugs are worth watching; the authors reported no new safety signals over the year [s2].

What is missing

Two limits frame all of this. First, these are 12-week and one-year measures of blood lipids, not evidence that obicetrapib prevents cardiovascular events; that question is being tested in a separate, still-running outcomes trial, and no lipid drug should be judged a success on the marker alone [s1]. Second, both analyses pool trials run and funded by the drug's developer, NewAmsterdam Pharma, whose employees are among the authors [s1][s2] — peer-reviewed, but company-sponsored data all the same.

The Lp(a) reduction, while genuine, is also modest next to the competition. Injectable small-interfering-RNA drugs have cut Lp(a) by more than 90% in early trials, and they too have yet to prove they prevent events. Obicetrapib's case is not depth but reach and convenience: an oral drug, taken alongside statins, that nudges several atherogenic lipids at once, in a combination that genetic studies suggest may lower risk more than moving either LDL or Lp(a) alone. Whether that translates into fewer events, and how it is priced against both statins and the new injectables, are the questions still open. This article describes trial findings and is not medical advice.